Noticias MorphoSys AG - MOR | Acciones NASDAQ

Herramientas de nivel profesional para inversores individuales.

MorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigen

– Die Ergebnisse der Phase-2-Studie L-MIND wurden auf der Jahrestagung der American Association for Cancer Research 2023 in einer...

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research...

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 – Monjuvi® U.S. net product sales of US$ 25.3 million (€ 24.7 million...

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

– Monjuvi® U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 – Presentation of preliminary results from...

MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

– Monjuvi® U.S. net product sales of US$ 23.3 million (€ 21.7 million) for the second quarter 2022, a 25% Q-Q growth and 29% Y-Y growth –...

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 PR Newswire SHANGHAI and...

MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210

Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory...

MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and...

MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings

Efficacy and safety data from the ongoing Phase 2 MANIFEST study of pelabresib in myelofibrosis will be featured during an oral presentation at...

MorphoSys AG Reports First Quarter 2022 Financial Results

– Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth – NCCN® updated...

MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

– Monjuvi® U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full...

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies...

Incyte et MorphoSys annoncent l'approbation par la Commission européenne de Minjuvi® (tafasitamab) en association avec le lénalidomide comme traitement pour les patients atteints de lymphome diffus à grandes cellules B (LDGCB) ...

- La décision de la Commission européenne est basée sur les données de l’étude L-MIND évaluant Minjuvi en association avec le lénalidomide comme...

Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi® (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem...

- Entscheidung der Kommission basiert auf Daten aus der Studie L-MIND zur Prüfung von Minjuvi in Kombination mit Lenalidomid als Behandlung von...

UpTickMeA$AP 6 meses hace

SCHEDULE 13D

Novartis BidCo Germany AG

Shared Voting Power
34,337,809

Percent of Class Represented by Amount in Row (11)
91.17%

The calculation of the foregoing percentage is based on 37,662,738 outstanding bearer shares (“Shares”) with no-par value (and excluding Shares held in treasury) of MorphoSys AG (the “Issuer”).

https://fintel.io/doc/sec-novartis-ag-1340243-sc-13da-2024-june-21-19895-8490

👍️0

ipo_dude 11 meses hace

PIPELINE ALONE reportedly worth $30usd/share.. then 30 million float. 1 million short. Plenty of cash!!’

👍️0

Monksdream 1 año hace

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

TenKay 7 años hace

MPSYY Froward Split 2 for 1.

http://otce.finra.org/DailyList

👍️0

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

MorphoSys AG (MOR)

Herramientas de nivel profesional para inversores individuales.

MOR Noticias

MorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigen

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210

MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings

MorphoSys AG Reports First Quarter 2022 Financial Results

MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte et MorphoSys annoncent l'approbation par la Commission européenne de Minjuvi® (tafasitamab) en association avec le lénalidomide comme traitement pour les patients atteints de lymphome diffus à grandes cellules B (LDGCB) ...

Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi® (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem...

MOR Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

MorphoSys AG (MOR) Noticias

MorphoSys AG (MOR)

Herramientas de nivel profesional para inversores individuales.

MOR Noticias

MorphoSys und Incyte präsentieren Fünf-Jahres-Ergebnisse der L-MIND-Studie, die bei Patienten mit rezidiviertem oder refraktärem DLBCL in Behandlung mit Monjuvi® (Tafasitamab-cxix) ein verlängertes, dauerhaftes Ansprechen zeigen

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210

MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings

MorphoSys AG Reports First Quarter 2022 Financial Results

MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte et MorphoSys annoncent l'approbation par la Commission européenne de Minjuvi® (tafasitamab) en association avec le lénalidomide comme traitement pour les patients atteints de lymphome diffus à grandes cellules B (LDGCB) ...

Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi® (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem...

MOR Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación